Search results for "Systemic."

showing 10 items of 756 documents

In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD

2011

Novel pharmacological strategies are aimed at the resolution of systemic inflammation in COPD potentiating peripheral blood T-cell (PBT-cell) apoptosis. Although muscarinic acetylcholine receptors (mAChRs) M(3) and choline-acetyltransferase (ChAT) participate in the airway inflammation of COPD, their role in PBT-cell apoptosis remains unexplained. We evaluated in PBT-cells from COPD patients, smoker (S) and control (C) subjects: (1) apoptosis (by annexin V binding), (2) mAChR M(3) and ChAT expression, acetylcholine (ACh)-binding; (3) choline levels in serum and PBT-cells extracts. We tested the effects of Tiotropium (Spiriva(®)) and hemicholinium-3 (HCh-3) on apoptosis, NFκB pathway, caspas…

MaleImmunologyScopolamine DerivativesApoptosisCD8-Positive T-LymphocytesPharmacologySystemic inflammationCholinergic AntagonistsCholineCholine O-AcetyltransferasePulmonary Disease Chronic ObstructiveAnnexinMuscarinic acetylcholine receptormedicineHumansImmunology and AllergyLymphocyte CountTiotropium BromideCaspaseAgedReceptor Muscarinic M3Caspase 8COPDbiologyCaspase 3Systemic inflammation Non-neuronal components of cholinergic system Caspases NF B pathwaybusiness.industryNF-kappa BHematologyTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesEnzyme ActivationApoptosisbiology.proteinFemalemedicine.symptombusinessAcetylcholineProtein BindingSignal Transductionmedicine.drugImmunobiology
researchProduct

The discharge of subthalamic neurons is modulated by inhibiting the nitric oxide synthase in the rat.

2005

The effects induced on the discharge of subthalamic spontaneously active neurons by inhibiting the enzyme nitric oxide synthase was studied in two groups of urethane-anesthetized rats. In the first group of animals (n = 10), the activity of subthalamic single units was recorded before and after the systemic administration of 7-nitro-indazole (7-NI, 50 mg/kg i.p.), a selective inhibitor of neuronal nitric oxide synthase. In the second group of rats (n = 15), Nomega-nitro-L-arginine methyl ester (L-NAME), another inhibitor of nitric oxide synthase, was iontophoretically administered while performing single unit extracellular recordings. The activity of most tested spontaneously discharging ne…

MaleIndazolesTime FactorsAction PotentialsBiologyPharmacologyNeurotransmissionSettore BIO/09 - FisiologiaNitric oxidechemistry.chemical_compoundL-NAMEmedicineReaction TimeAnimalsEnzyme InhibitorsRats WistarNeuronsAnalysis of VarianceIontophoresisDose-Response Relationship Drug7-Nitro-indazoleIn vivo unit recordingGeneral NeuroscienceSubthalamic nucleuNitric oxideRatsNitric oxide synthaseSubthalamic nucleusmedicine.anatomical_structureNG-Nitroarginine Methyl EsterBiochemistrychemistrySubthalamusBasal gangliaExcitatory postsynaptic potentialSystemic administrationbiology.proteinNeuronNitric Oxide SynthaseNeuroscience letters
researchProduct

The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis.

2013

Systemic sclerosis (SSc) is a fibrotic autoimmune disease in which the genetic component plays an important role. One of the strongest SSc association signals outside the human leukocyte antigen (HLA) region corresponds to interferon (IFN) regulatory factor 5 (IRF5), a major regulator of the type I IFN pathway. In this study we aimed to evaluate whether three different haplotypic blocks within this locus, which have been shown to alter the protein function influencing systemic lupus erythematosus (SLE) susceptibility, are involved in SSc susceptibility and clinical phenotypes. For that purpose, we genotyped one representative single-nucleotide polymorphism (SNP) of each block (rs10488631, r…

MaleLinkage disequilibrium:Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings]Polimorfismo de nucleótido simpleSLElcsh:MedicineAutoimmunityGenome-wide association studyLinkage DisequilibriumScleroderma:Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Gene Frequency:Named Groups::Persons::Population Groups::Continental Population Groups::European Continental Ancestry Group [Medical Subject Headings]Risk FactorsIRF5Genetics of the Immune SystemLupus Erythematosus Systemic:Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Scleroderma Systemic [Medical Subject Headings]skin and connective tissue diseaseslcsh:ScienceMultidisciplinary:Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus Systemic [Medical Subject Headings]Predisposición genética a la enfermedad:Phenomena and Processes::Genetic Phenomena::Genetic Linkage::Linkage Disequilibrium [Medical Subject Headings]:Phenomena and Processes::Genetic Phenomena::Genotype::Genetic Predisposition to Disease [Medical Subject Headings]PhenotypeInterferon Regulatory FactorsSYSTEMIC SCLEROSISMedicineEvaluation of complex medical interventions Auto-immunity transplantation and immunotherapy [NCEBP 2]FemaleIRF5; SLE; TYPE I INTERFERON; SYSTEMIC SCLEROSISHaplotiposResearch ArticleFactores de riesgoImmunology:Chemicals and Drugs::Amino Acids Peptides and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Adaptor Proteins Signal Transducing::Interferon Regulatory Factors [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]:Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings]Single-nucleotide polymorphismHuman leukocyte antigenBiologyPolymorphism Single NucleotideWhite PeopleAutoimmune DiseasesRheumatologyLupus eritematoso sistémicoGeneticsHumansGenetic Predisposition to DiseaseGrupo de ascendencia continental europeaAlleleBiologyAllele frequencyAllelesGenetic Association Studies:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings]Scleroderma SystemicHaplotypelcsh:R:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genetic Loci [Medical Subject Headings]Human Genetics:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism Genetic [Medical Subject Headings]Factores reguladores del interferónHaplotypesDesequilibrio de ligamiento:Check Tags::Female [Medical Subject Headings]Genetic LociTYPE I INTERFERONGenetics of DiseaseImmunologyGenetic PolymorphismClinical Immunologylcsh:Q:Phenomena and Processes::Genetic Phenomena::Gene Frequency [Medical Subject Headings]Population GeneticsIRF5PLoS ONE
researchProduct

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

2022

Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need of further research to gain their incorporation into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that is needed to take clinical decisions in individual patients so that the rec…

MaleLiver CancerPrognosis predictionmedicine.medical_specialtyCarcinoma HepatocellularTare weightliver transplantation TACEAFPClinical Trials and Supportive ActivitiesClinical SciencesPsychological interventionSeverity of Illness IndexablationsurvivalArticleTAREsurgeryRare DiseasesClinical ResearchMedicineHepatectomyHumansHCCIntensive care medicineStaging systemNeoplasm StagingCancerHepatologyGastroenterology & Hepatologybusiness.industryLiver DiseaseCarcinomaLiver NeoplasmsALBI scoreHepatocellularsystemic treatmentMiddle Agedmedicine.diseasePrognosisBCLCGood Health and Well BeingHepatocellular carcinomaPublic Health and Health ServicesTreatment strategyFemalebusinessLiver cancerDigestive Diseases
researchProduct

Circulating CSF-1 Promotes Monocyte and Macrophage Phenotypes that Enhance Lupus Nephritis

2009

Macrophages mediate kidney disease and are prominent in a mouse model (MRL- Fas lpr ) of lupus nephritis. Colony stimulating factor-1 (CSF-1) is the primary growth factor for macrophages, and CSF-1 deficiency protects MRL- Fas lpr mice from kidney disease and systemic illness. Whether this renoprotection derives from a reduction of macrophages and whether systemic CSF-1, as opposed to intrarenal CSF-1, promotes macrophage-dependent lupus nephritis remain unclear. Here, we found that increasing systemic CSF-1 hastened the onset of lupus nephritis in MRL- Fas lpr mice. Using mutant MRL- Fas lpr strains that express high, moderate, or no systemic CSF-1, we detected a much higher tempo of kidne…

MaleMacrophage colony-stimulating factorMice Inbred MRL lprLupus nephritisMice TransgenicInflammationKidneyMonocytesMiceimmune system diseasesmedicineAnimalsHumansskin and connective tissue diseasesCell ProliferationInflammationMice Inbred BALB CMice Inbred C3HSystemic lupus erythematosusbiologyCD68business.industryMacrophage Colony-Stimulating FactorMacrophagesMonocyteGeneral MedicineMonocyte proliferationmedicine.diseaseLupus NephritisMice Inbred C57BLDisease Models AnimalBasic ResearchPhenotypemedicine.anatomical_structureIntegrin alpha MNephrologyImmunologybiology.proteinFemalemedicine.symptombusinessJournal of the American Society of Nephrology
researchProduct

Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9

2010

Lupus-prone mice develop a chronic inflammatory response to cutaneous injury that depends on the production of type I interferon, TLR7, and TLR9.

MaleMice 129 StrainImmunologyGene ExpressionInflammationchemical and pharmacologic phenomenaMice Inbred StrainsReceptor Interferon alpha-betaBiologySkin DiseasesArticleProinflammatory cytokinePathogenesisTLR9MiceAutoimmune skin inflammationimmune system diseasesNucleic AcidsmedicineImmunology and AllergyAnimalsLupus Erythematosus SystemicReceptorskin and connective tissue diseasesTLR7SkinAutoimmune skin inflammation; TLR7; TLR9; plasmacytoid dendritic cells.Mice KnockoutPlasmacytoid dendritic cell activationLupus erythematosusReverse Transcriptase Polymerase Chain ReactionTLR9virus diseaseshemic and immune systemsTLR7DNADendritic Cellsmedicine.diseaseFlow CytometryMice Inbred C57BLplasmacytoid dendritic cells.Toll-Like Receptor 7Toll-Like Receptor 9ImmunologyMyeloid Differentiation Factor 88CytokinesFemalemedicine.symptomThe Journal of Experimental Medicine
researchProduct

Stimulatory and inhibitory effects of ethanol on hippocampal acetylcholine release

1998

Using the microdialysis technique and sensitive HPLC procedures for the determination of acetylcholine (ACh) and ethanol, we investigated the release of ACh in rat hippocampus after acute ethanol administration. Systemic administration of ethanol (0.8 and 2.4 g/kg i.p.) led to peak ethanol concentrations of 21 and 42 mM in the hippocampus, respectively. The high dose caused a long-lasting inhibition of basal ACh release by up to 33%. Local infusion of scopolamine (1 microM) enhanced hippocampal ACh release up to eightfold in the presence of neostigmine (10 microM), and this stimulated release was also inhibited after systemic ethanol administration (by up to 45%). The low dose of ethanol (0…

MaleMicrodialysisMicrodialysisScopolamineHippocampusStimulationMuscarinic AntagonistsHippocampal formationPharmacologyHippocampuschemistry.chemical_compoundmedicineAnimalsRats WistarChromatography High Pressure LiquidPharmacologyEthanolEthanolCentral Nervous System DepressantsGeneral MedicineAcetylcholineRatsKineticschemistrySystemic administrationCholinergicExtracellular SpaceAcetylcholinemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Early and mid-term effects of obstructive apneas in myocardial injury and inflammation.

2011

Abstract Background Obstructive sleep apnea (OSA) is associated with cardiovascular disorders, but the different comorbidities in OSA patients make it difficult to know their specific effects on the development of cardiovascular injury. The aim of the present study was to investigate whether recurrent obstructive apneas could lead to myocardial injury. Methods Thirty-six male Sprague–Dawley rats (300–350 g) were either acutely (3 h) or sustainably (5 h/day, for 10 days) subjected to obstructive apneas with a pattern of 15 s each, 60 apneas/h. Corresponding control groups were formed for the acute and sustained models. To assess the induction of systemic inflammation, IL1-β was measured in p…

MaleObstructive sleep apnea Myocardial injury Inflammation Animal modelsmedicine.medical_specialtyPathologyHeart diseaseHeart DiseasesInterleukin-1betaInflammationApoptosisSettore MED/10 - Malattie Dell'Apparato RespiratorioSystemic inflammationRats Sprague-DawleyInternal medicinemedicineAnimalsInflammationSleep Apnea Obstructivebusiness.industryMyocardiumSleep apneaGeneral Medicinemedicine.diseaseRatsObstructive sleep apneaDisease Models AnimalApoptosisInitial phaseAcute DiseaseCardiologyDisease ProgressionCardiovascular Injurymedicine.symptombusinessSleep medicine
researchProduct

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

2013

Bevacizumab is a humanized anti-VeGF monoclonal antibody able to produce clinical beneit in advanced non-squamous non-small cell lung cancer (nsCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or biological markers have been identiied and validated for baseline patient selection. preclinical indings suggest an important role for myeloid-derived inlammatory cells, such as neutrophils and monocytes, in the development of VeGF-independent angiogenesis. We conducted a retrospective analysis to investigate the role of peripheral blood cells count and of an inlammatory index, the neutrophil-toly…

MaleOncologyCancer ResearchLung NeoplasmsNeutrophilsmedicine.medical_treatmentPlatinum CompoundsMonocyteCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsNeutrophil-to-lymphocyte ratioUnivariate analysisadvanced non-small cell lung cancerMiddle AgedBevacizumabAngiogenesiTreatment OutcomeOncologyMolecular MedicineFemalemedicine.symptomLung cancermedicine.drugmedicine.medical_specialtyBevacizumabInflammationAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicinemedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioLung cancerAdverse effectAgedNeoplasm StagingRetrospective StudiesPharmacologyInflammationChemotherapyBedside to Bench ReportPlatelet Countbusiness.industryRetrospective cohort studymedicine.diseaseMultivariate AnalysisImmunologybusinessSystemic inflammatory status
researchProduct

Olfaction in chemotherapy for head and neck malignancies

2015

Abstract Objective Systemic chemotherapy for different malignancies occurs alongside various side effects, including reduced sensory function. To date, little is known about the effect of chemotherapeutic agents on olfaction. The aim of this study was to provide new data about changes in sense of smell during chemotherapy among patients with advanced squamous cell carcinomas of the head and neck region. Methods In a prospective, controlled cohort study of patients undergoing up to three courses of chemotherapy (cis- or carboplatin, 5-fluorouracil and docetaxel), olfaction was evaluated prior to and directly following completing a cycle, as well as 3 weeks later with the beginning of the nex…

MaleOncologymedicine.medical_treatmentDocetaxelSystemic therapyCarboplatinCohort StudiesOlfaction Disorderschemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective Studies030212 general & internal medicineAged 80 and overSmokingAge FactorsGeneral MedicineMiddle AgedDocetaxelHead and Neck NeoplasmsSensory Thresholds030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleTaxoidsFluorouracilmedicine.drugCohort studyAdultmedicine.medical_specialtyDifferential ThresholdOlfaction03 medical and health sciencesInternal medicinemedicineHumansLaryngeal NeoplasmsAgedCisplatinChemotherapySquamous Cell Carcinoma of Head and Neckbusiness.industryCancerPharyngeal Neoplasmsmedicine.diseaseCarboplatinSurgeryOtorhinolaryngologychemistryControlled Before-After StudiesSurgeryCisplatinbusinessAuris Nasus Larynx
researchProduct